Sydney Lupkin

Merck traditionally has been a leader in vaccines but has not had success with a COVID-19 vaccine. It’s lending a hand to Johnson & Johnson, where production is running significantly behind schedule.

The Centers for Disease Control and Prevention released plans for the distribution of coronavirus vaccines. The logistical challenges could be as daunting as the scientific ones.

The federal government is in charge of distributing one of the few treatment options for COVID-19: the antiviral drug remdesivir. But how are decisions made about which states need it most?

Federal government makes sixth and largest deal for coronavirus vaccine candidate as part of Operation Warp Speed.

Companies that made hats, socks and teddy bears have started producing surgical masks to protect people from COVID-19. Some sellers exaggerate their standing with the Food and Drug Administration.

An experimental COVID-19 medicine that has been shown to shorten the time people with severe illness have to stay in the hospital finally has a price tag that’s lower than some analysts expected.

As Operation Warp Speed pushes to develop a COVID-19 vaccine in record time, the number of candidates is being narrowed. The factors guiding the decision about which projects to fund is unclear.

New research indicates that insurers are covering far fewer drugs than they did a decade ago. The reduction in options can interrupt care and leave people with hard choices at the pharmacy counter.

Two nearly identical drug implants have very different prices. The one for kids has a list price of $37,300. For adults, it’s $4,400. A dad fought for his daughter to be able to get the cheaper drug.

Drugs to treat multiple sclerosis can run $70,000 a year or more. Patients hoped competition from a generic version of one of the most popular brands would spur relief, but prices went up. Here’s why.